Ionis and AstraZeneca Reports Results of P-IIb (ETESIAN) Study of ION449 for the Treatment of Hypercholesterolemia at ACC 2022
Shots:
- The P-IIb (ETESIAN) study evaluates the efficacy, safety & tolerability of ION449 (50 & 90mg) vs PBO in 119 patients aged 18-75yrs. with high-risk hypercholesterolemia. The therapy is being developed by AstraZeneca
- The study met its 1EPs & 2EPs i.e., 79% & 94% reduction in serum LDL-C levels & PCSK9 levels, both doses reached significant & clinical reductions in LDL-C & PCSK9 levels from baseline (73% & 79% vs 2%) & (89% & 94% vs 5%) & were maintained until 14wks., was well tolerated during the 12wk. treatment period & 12wk. follow up period
- ION449 is an investigational antisense therapy & was designed to reduce blood cholesterol levels in patients with hypercholesterolemia by targeting PCSK9
Ref: PR Newswire | Image: Ionis
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
